GWAS-identified genetic variants associated with medication-assisted treatment outcomes in patients with opioid use disorder: a systematic review and meta-analysis protocol.
Genome-wide association
Medication-assisted treatment
Opioid use
Pharmacogenetics
Protocol
SNP
Systematic review
Treatment response
Journal
Systematic reviews
ISSN: 2046-4053
Titre abrégé: Syst Rev
Pays: England
ID NLM: 101580575
Informations de publication
Date de publication:
01 09 2020
01 09 2020
Historique:
received:
20
04
2020
accepted:
21
08
2020
entrez:
3
9
2020
pubmed:
3
9
2020
medline:
22
6
2021
Statut:
epublish
Résumé
The burden of opioid use disorder (OUD) has been increasing in North America. Administration of medication-assisted treatments (MATs) for OUD on an individual-dose basis has been shown to affect patient responses to treatment, proving to be, on occasion, dangerous. A genetic basis has been identified for some MAT responses in a candidate gene context, but consensus has not been reached for any genome-wide significant associations. This systematic review aims to identify and assess any genetic variants associated with MAT patient outcomes at genome-wide significance. The databases searched by the authors will be: MEDLINE, Web of Science, EMBASE, CINAHL and Pre-CINAHL, GWAS Catalog, GWAS Central, and NIH Database of Genotypes and Phenotypes. A title and abstract screening, full-text screening, data extraction, and quality assessment will be completed in duplicate for each study via Covidence. Treatment outcomes of interest include continued opioid use or abstinence during treatment or at follow-up, time to relapse, treatment retention rates, opioid overdose, other substance use, comorbid psychiatric disorders, risk taking behaviors, MAT plasma concentrations, and mortality rates. Analysis methods applied, if appropriate, will include random effects meta-analysis with pooled odds ratios for all outcomes. Subgroup analyses will also be implemented, when possible. This systematic review can hopefully inform the direction of future research, aiding in the development of a safer and more patient-centered treatment. It will be able to highlight genome-wide significant variants that are replicable and associated with MAT patient outcomes. This systematic review protocol has been registered with the International Prospective Register of Systematic Reviews (PROSPERO) (registration ID CRD42020169121).
Sections du résumé
BACKGROUND
The burden of opioid use disorder (OUD) has been increasing in North America. Administration of medication-assisted treatments (MATs) for OUD on an individual-dose basis has been shown to affect patient responses to treatment, proving to be, on occasion, dangerous. A genetic basis has been identified for some MAT responses in a candidate gene context, but consensus has not been reached for any genome-wide significant associations. This systematic review aims to identify and assess any genetic variants associated with MAT patient outcomes at genome-wide significance.
METHODS
The databases searched by the authors will be: MEDLINE, Web of Science, EMBASE, CINAHL and Pre-CINAHL, GWAS Catalog, GWAS Central, and NIH Database of Genotypes and Phenotypes. A title and abstract screening, full-text screening, data extraction, and quality assessment will be completed in duplicate for each study via Covidence. Treatment outcomes of interest include continued opioid use or abstinence during treatment or at follow-up, time to relapse, treatment retention rates, opioid overdose, other substance use, comorbid psychiatric disorders, risk taking behaviors, MAT plasma concentrations, and mortality rates. Analysis methods applied, if appropriate, will include random effects meta-analysis with pooled odds ratios for all outcomes. Subgroup analyses will also be implemented, when possible.
DISCUSSION
This systematic review can hopefully inform the direction of future research, aiding in the development of a safer and more patient-centered treatment. It will be able to highlight genome-wide significant variants that are replicable and associated with MAT patient outcomes.
SYSTEMATIC REVIEW REGISTRATION
This systematic review protocol has been registered with the International Prospective Register of Systematic Reviews (PROSPERO) (registration ID CRD42020169121).
Identifiants
pubmed: 32873330
doi: 10.1186/s13643-020-01461-z
pii: 10.1186/s13643-020-01461-z
pmc: PMC7466496
doi:
Substances chimiques
Analgesics, Opioid
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
200Subventions
Organisme : CIHR
ID : PJT-156306
Pays : Canada
Références
PLoS One. 2014 Jan 29;9(1):e86114
pubmed: 24489693
Expert Opin Pharmacother. 2009 Aug;10(11):1727-40
pubmed: 19538000
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
J Gen Intern Med. 2010 Apr;25(4):305-9
pubmed: 20087676
Am J Drug Alcohol Abuse. 1994;20(2):173-97
pubmed: 8042602
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
Int J Epidemiol. 2012 Feb;41(1):273-86
pubmed: 22253303
J Subst Abuse Treat. 2010 Jul;39(1):22-31
pubmed: 20418051
BMC Genet. 2015 May 15;16:50
pubmed: 25975208
J Clin Epidemiol. 2011 Apr;64(4):380-2
pubmed: 21185693
Curr Psychiatry Rev. 2014 May;10(2):156-167
pubmed: 25242908
BMJ. 2017 Apr 26;357:j1550
pubmed: 28446428